Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.
2024年8月22日,伊頓製藥公司(「伊頓」或「公司」)(納斯達克:ETON)是一家專注於開發和商業化罕見病治療藥品的創新藥品公司,宣佈今天將參加在紐約市舉行的H.C. Wainwright第26屆全球投資大會。
The Company's presentation by Sean Brynjelsen, Chief Executive Officer, will be available on demand commencing on September 9, 2024, at 7am ET.
公司首席執行官肖恩·布林伊爾森的演講將於2024年9月9日上午7點以視頻點播形式提供。
Investors can access the presentation here.
投資者可以在此處觀看演講。
To schedule an in-person 1x1 meeting with the Company, please contact Corporate Access at H.C. Wainwright.
要安排與公司進行面對面的1對1會議,請聯繫H.C. Wainwright的企業接觸團隊。
About Eton Pharmaceuticals
關於伊頓製藥公司
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. For more information, please visit our website at .
伊頓是一家專注於研發和商業化罕見病治療的創新性製藥公司。該公司目前擁有五種罕見病產品:ALKINDI SPRINKLE,PKU GOLIKE,Carglumic Acid,Betaine Anhydrous和Nitisinone。公司目前處於三個尾期開發的產品,包括ET-400,ET-600和ZENEO水楊酸巴利昂自動注射器。欲了解更多信息,請訪問我公司網站。
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
投資者關係:
英未泰客,內部溝通公司
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
來源:伊頓製藥公司。
Source: Eton Pharmaceuticals
來源:伊頓製藥公司
譯文內容由第三人軟體翻譯。